Table 2.
Effect of metabolic syndrome and treatment on CRC survival.
| Variable | Crude HR | 95% CI | ∗Adjusted HR | 95% CI |
|---|---|---|---|---|
| MetS | ||||
| No | Ref | - | - | |
| Yes | 0.89 | 0.57-1.38 | 1.01 | 0.64-1.59 |
| ACEI use | ||||
| No | Ref | - | - | |
| Yes | 2.06 | 1.19-3.56 | 1.46 | 0.89-2.38 |
| Other anti-HTN | ||||
| No | Ref | - | - | |
| Yes | 1.89 | 0.24-14.67 | 1.74 | 0.21-14.70 |
| Metformin use | ||||
| No | Ref | - | - | |
| Yes | 0.38 | 0.20 -0.71 | 0.46 | 0.25-0.84 |
| Insulin use | ||||
| No | Ref | - | - | |
| Yes | 1.28 | 1.09 -1.75 | 1.73 | 1.02-2.97 |
| Statin use | ||||
| No | Ref | - | - | |
| Yes | 0.42 | 0.25-0.74 | 0.58 | 0.30-0.97 |
MetS: metabolic syndrome. ∗Adjusted for age, sex, and cancer stage and tumor differentiation, cancer treatment, BMI, alcohol, and smoking.